$OSCR announced a new partnership with HealthEx. Members can now securely connect their medical records to the Oscar app, allowing its AI assistant, Oswell, to provide more personalized healthcare guidance. I love seeing Oscar continue to build out the technology side of its business.
Found these ETF's about a year ago. They have been doing really well YTD, as the whole sector has also. Holding both does not have much overlap. Interesting etfs to hold if your looking for a healthcare holding. Check them out. $XDNA $FBT
Been looking at $TMDX. The part I’m trying to figure out is the planes. They sell the system that keeps an organ viable for transplant and can handle getting it to the hospital. I can see why a transplant center would want one team handling both. Revenue +41% last quarter, but operating margin went from 16.2% to 13.9%. Some of that is trial spending and expansion. Around $91 I’m still watching. I want to see whether they can do more cases with the network they’ve already built.
Tech had a rough week. Health care earnings did not. Of 23 S and P 500 health care companies reporting last week, 22 beat EPS estimates and all 23 grew revenue year over year. Here are 4 worth researching. 👇 📌 The Watchlist 1. AbbVie | $ABBV: Drugmaker known for immunology and neuroscience medicines. Q3 revenue was $17.40 billion, up 10.3 percent year over year, adjusted EPS was $3.82, and it raised 2026 adjusted EPS guidance to $13.95 to $13.99, with Skyrizi sales up 22.7 percent to $5.78 billion. 2. Gilead Sciences | $GILD: Maker of HIV and antiviral medicines. Q3 revenue was $8.30 billion, up 7 percent year over year, adjusted EPS was $2.55, and it raised full year 2026 product sales guidance to $31.0 billion to $31.3 billion, with HIV sales up 18 percent to $6.2 billion. 3. Incyte | $INCY: Biotech focused on cancer and immune diseases, led by Jakafi and Opzelura. Q3 total revenue was $1.56 billion, up 14 percent year over year, and it raised 2026 total net sales guidance to $5.21 billion to $5.30 billion, with Opzelura sales up 36 percent to $255 million. 4. Bristol Myers Squibb | $BMY: Drugmaker with cancer, immunology and heart medicines. Q3 revenue was $13.07 billion, up 7 percent year over year, and adjusted EPS was $1.35, topping the $1.09 estimate. 📌 The Part Worth Saving A beat is a reason to research a stock. It is not a reason to buy blindly. Look for: - Revenue growth with the beat, not cost cuts alone - Guidance raised, not just a one quarter beat - One time charges separated from the core business, like Incyte's Vega acquisition charge - Patent and pricing risks still in view, like Gilead's disclosed Biktarvy Medicare price cut starting in 2028 - What the next report must repeat for the beat to hold The best question: Which of these beats looks repeatable next quarter, and which was a one time lift? Education only, not financial advice.read more
Health care stocks jumped into the afternoon after Democrats regained majorities in the House and Senate. Analysts said drug pricing legislation is unlikely to dominate the new agenda, and existing Medicare price negotiations expand automatically each year, easing near term policy risk for the sector. Here are 4 worth researching. 👇 📌 The Watchlist 1. AdaptHealth | $AHCO: Home medical equipment and home health provider. Shares jumped 17.7% in the afternoon session, after its third quarter raised full year revenue guidance to $2.88 billion to $2.90 billion. 2. Acadia Healthcare | $ACHC: Behavioral health care provider running psychiatric hospitals and outpatient programs. Shares jumped 10.5% in the afternoon session with the wider health care rally. 3. Align Technology | $ALGN: Digital orthodontics company focused on clear aligner treatment. Shares jumped 9.8% in the afternoon session as health care names moved higher. 4. DexCom | $DXCM: Continuous glucose monitoring systems for people with diabetes. Shares jumped 6.5% in the afternoon session, a smaller move than the other three but part of the same rally. 📌 The Part Worth Saving A policy relief rally is a reason to research a stock. It is not a reason to buy blindly. Look for: - Real revenue and cash flow, not just a one day relief move - What reimbursement or pricing rules actually change next - Whether the jump holds after the first session - A business that can grow even if the policy story fades The best question: Which of these four would you research first, the biggest mover or the steadiest business? Education only, not financial advice.read more
Washington just changed the math for health insurers. On November 16, Medicare proposed a sweeping audit rule for Medicare Advantage plans. At midday the whole managed care group was sliding, and the Dow fell about 1.2% toward 50,000. Here are 4 worth researching. 👇 📌 The Watchlist 1. UnitedHealth Group | $UNH: The largest Medicare Advantage insurer in the US. It fell about 8% at midday after dropping 5.4% on Tuesday, with the proposed audits reaching back to payment year 2018. 2. Humana | $HUM: Medicare Advantage is central to its business, with about 7 million members. It fell about 9% at midday, the biggest S&P 500 loser of the day. 3. Elevance Health | $ELV: One of the largest US health insurers, with a large Medicare Advantage book. It fell about 6% at midday as the whole managed care group slid. 4. Centene | $CNC: A major managed care insurer focused on government health programs. It fell about 6% at midday on the same audit fears. 📌 The Part Worth Saving A regulatory headline is a reason to research a stock. It is not a reason to buy blindly. Look for: - How much of each insurer's revenue comes from Medicare Advantage - What the proposed audits could claw back, and over how many years - Whether the company has reserved for audit exposure yet - What the comment period, open until January 19, could change The best question: which insurer can still earn its margins if the audits recover about $9 billion a year across the industry? Education only, not financial advice.read more